The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2022Parkinson’s Disease Treatment Evaluation and Access Strategy: Phase 1
Study Rationale: Core funding programs at The Michael J. Fox Foundation (MJFF) have historically focused on research to understand, measure, and treat Parkinson’s disease (PD). MJFF is now seeking to...
-
Novel PET Tracer Development Program, 2022Discovery of Novel Radiolabeled Tracers for Imaging Microglia Associated with Neuroinflammation in Parkinson’s disease
Study Rationale: Parkinson´s disease (PD) is associated with neuroinflammation and the activation of microglia, cells that belong to the brain’s immune system. A protein called Colony stimulating...
-
Research Grant, 2022Longitudinal Endpoint Optimization to Provide an Assessment of Relevant Drugs in Parkinson’s Disease (LEOPARD-PD)
Study Rationale: The Parkinson’s Disease-Health Index (PD-HI) is a novel, disease specific patient-reported outcome (PRO) measure designed for use in clinical trials to track clinically meaningful...
-
Research Resources Imaging Program, 2022Developing Actionable Machine Learning (AML) Methods for Diagnosing, Monitoring and Treating Parkinson’s Disease
Study Rationale: In today’s modern age of computational smart health, actionable machine learning (AML) methods automatically and progressively learn how to correctly answer queries about the state of...
-
Biomarkers to Support Therapeutic Trials Program, 2022Identifying Biomarkers for a Mitochondrial Subtype of Parkinson’s Disease
Study Rationale: Increasing evidence suggests that the disorder we refer to as Parkinson’s disease (PD) might represent several diseases, each driven by different biological mechanisms. The...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2022Glucocerebrosidase Activation as a Therapeutic Strategy for Parkinson’s Disease
Study Rationale: Mutations in GBA1, the gene that encodes glucocerebrosidase (GCase), diminish GCase activity in an estimated 7 to 10% of people with Parkinson’s disease (PD). In addition, reduced...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.